-
Cholecystokinin Octapeptide Ammonium: Evidence Map
2026-10-07
Cholecystokinin octapeptide ammonium is a sulfated brain–gut peptide whose receptor, redox, and cardiac signaling should be interpreted as a connected but context-limited evidence chain. This article examines the CCK-8 ammonium identity, the NOX4–PGC-1α–PPAR pathway, and the boundaries between cardiac, neuronal, immune, and behavioral findings.
-
Bortezomib, PS-341, and Stress-Adaptation Biology
2026-10-07
Bortezomib (PS-341) is best understood in this context as a pharmacological probe of proteasome-associated stress, not as a standalone explanation for cell death. A 2025 study in human breast cancer cells identifies caspase 3 and caspase 7 as contributors to cytoprotective autophagy and DNA-damage responses during non-lethal stress, while also revealing important limits on how these findings can be translated across cancer models.
-
HyperScript RT SuperMix for qPCR and FBN1
2026-10-06
HyperScript RT SuperMix for qPCR can support transcript-level investigation of FBN1 variants through consistent cDNA synthesis for qPCR. This article distinguishes the genetic findings of a Marfan syndrome case report from the additional RNA evidence needed to interpret variant function.
-
Pitavastatin (NK-104): Product Overview
2026-10-05
Pitavastatin (NK-104; SKU B1124) is an APExBIO-listed research compound described for HMG-CoA reductase and cholesterol-biosynthesis research. No matched paper evidence was supplied, so the product record does not establish pathway effects, model performance, or therapeutic applicability.
-
Omeprazole A2845: Product Overview
2026-10-05
APExBIO lists Omeprazole (A2845) as a research-use H+,K+-ATPase inhibitor. This overview is limited to catalog-reported identity and conceptual scope; no matched paper evidence was provided.
-
Trolox as a Redox Interpretation Tool
2026-10-04
Trolox is more than a general antioxidant: it can help researchers distinguish broad redox protection from lipid-peroxidation-driven cell death. This evidence-focused guide connects Trolox with oxidative injury research, ferroptosis interpretation, and high-throughput antioxidant screening while defining important limits.
-
Telatinib: Interpreting VEGFR-Targeted Evidence
2026-10-03
Telatinib, also known as BAY 57-9352, is a multitarget kinase inhibitor for studying VEGFR, c-Kit, and PDGFR signaling. This evidence-focused guide explains how to interpret its activity in angiogenesis and triple-negative breast cancer research without overstating phenotype-based findings.
-
6-OHDA Hydrochloride: Mechanism & Use
2026-10-02
6-OHDA hydrochloride is a catecholaminergic neurotoxin used to create targeted experimental lesions, especially in Parkinsonian animal models. Its value depends on transporter-mediated uptake, controlled delivery, lesion verification, and clear separation between dopaminergic selectivity and broader catecholamine toxicity.
-
IL-7, Human Recombinant: Biology and Use
2026-10-01
IL-7, human recombinant is a research cytokine for studying IL-7 receptor signaling, lymphocyte survival, and T-cell biology. The strongest evidence supports pathway-focused and ex vivo immune-cell applications, while product-specific potency and formulation details must be confirmed from the lot documentation.
-
Recombinant Human FGF-19: Applied Assays
2026-10-01
Build controlled FGFR4-binding, proliferation, and metabolic signaling workflows with a tag-free FGF-19 protein. This guide shows how to use the reagent as an endocrine-metabolic probe alongside, but not as a substitute for, the WIP1–p38 MAPK–pyroptosis model of septic acute kidney injury.
-
SpCas9 mRNA (ARCA, 5mCTP, ψUTP) Guide
2026-09-30
SpCas9 mRNA (ARCA, 5mCTP, ψUTP) provides an RNA-based source of Streptococcus pyogenes Cas9 for guide-directed genome editing in eukaryotic research systems. This guide covers handling, experimental setup, and quality controls while distinguishing product specifications from workflow recommendations; it does not claim directly matched paper performance or replace guide-, delivery-, and cell-specific optimization.
-
Caffeine Workflows for Cancer and Metabolism
2026-09-30
Caffeine supports distinct laboratory use-cases, from millimolar sarcoma-cell assays to energy-balance studies in diet-induced obesity models. This workflow-focused guide emphasizes formulation control, combination testing with valproic acid, and careful separation of caffeine biology from emerging ALDH2-centered cardiovascular research.
-
ACSL4 Drives Decidualization via Fatty Acid β-Oxidation
2026-09-29
This study identifies ACSL4-driven fatty acid β-oxidation, rather than lipid droplet accumulation, as a functional metabolic pathway supporting endometrial decidualization. By combining human and mouse tissue analysis, genetic perturbation, pharmacological intervention, and implantation assays, it links lipid catabolism to stromal-cell differentiation and embryo implantation.
-
In Situ CAR-M Design for Hepatocellular Carcinoma
2026-09-29
The reference study develops an in situ programmed CAR-macrophage platform for hepatocellular carcinoma by combining GPC3 recognition with IFN-γ secretion and a dominant-negative SIRPα extracellular domain. Using LNP-mRNA delivery, single-cell profiling, murine tumor models, and human HCC organoids, the work shows how coordinated macrophage activation and CD47–SIRPα checkpoint disruption can strengthen phagocytosis and remodel the tumor microenvironment.
-
Mildronate Lipidoids for Lower-Inflammation mRNA Vaccines
2026-09-28
A 2024 ACS Nano study reports that a low-dose mildronate-derived lipidoid formulation, mLNP-69, can deliver mRNA while producing less local inflammation than an SM102-based comparator. Its performance in prophylactic and therapeutic B16OVA melanoma models highlights the importance of evaluating delivery efficiency and inflammatory effects together.